The Future of Sepsis Management: Systems Immunology and Precision Medicine

Sepsis

(Adobe Stock unknown)

Introduction: Sepsis as a Major Medical Emergency

Sepsis represents an abnormal and life-threatening reaction to infection that leads to multi-organ dysfunction and failure. It remains one of the least recognized yet significant causes of mortality worldwide, accounting for nearly 20% of all annual deaths. The COVID-19 pandemic emphasized sepsis’s critical role in severe viral infections, with most COVID-19-related deaths displaying molecular characteristics similar to sepsis. Despite this burden, the current management paradigm—focused on antimicrobials and supportive care—fails to account for sepsis’s mechanistic complexity and heterogeneity.

In a recent study published in Frontiers, investigators discuss the recent advancements in systems immunology, including multiomics, machine learning, and network biology analysis, which offer a promising path toward precision medicine in sepsis care. This approach enables early diagnosis, classification of patients into mechanistically distinct “endotypes,” and the development of personalized, stage-specific immune-directed therapies.

“We argue that collaborative multidisciplinary and multistakeholder research and action to transform the diagnosis and management of sepsis should be a priority to mitigate against future pandemics, as well as the present and rising burden from sepsis,” the authors wrote.

The Complexity of Sepsis and the Need for Systems Immunology

Sepsis is characterized by extreme heterogeneity in causes, clinical presentation, and disease progression. Current diagnostic criteria, such as the Sequential Organ Failure Assessment (SOFA) score, are imprecise and often result in delayed therapy, increasing mortality rates. The challenge in sepsis management lies in its complex immune dysfunction, which involves both hyperinflammatory and immunosuppressive states.

Systems immunology provides a holistic approach to understanding sepsis by integrating various high-throughput omics datasets, such as:

• Transcriptomics (RNA sequencing): Identifies differentially expressed genes in sepsis patients.
• Proteomics and Metabolomics: Elucidates changes in protein and metabolic pathways.
• Epigenomics: Investigates persistent immune alterations due to sepsis.

By leveraging these datasets with AI-driven analytics, researchers can identify novel biomarkers for early detection, classify sepsis into endotypes, and predict disease trajectories.

Sepsis Endotypes: A New Paradigm for Diagnosis and Treatment

The authors explain that recent studies using machine learning and clustering techniques have revealed that sepsis is not a singular entity but comprises multiple mechanistically distinct endotypes. These include:

1. Neutrophilic-Suppressive (NPS): Characterized by immune suppression, high mortality.
2. Inflammatory (INF): Hyperinflammatory response leading to organ failure.
3. Interferon (IFN): Associated with viral responses.
4. Adaptive (ADA): Better prognosis due to active immune adaptation.
5. Innate Host Defense (IHD): Strong innate immune response aiding recovery.

Identifying these endotypes allows for precision-targeted therapies rather than the current one-size-fits-all approach.

Systems Immunology for Early Sepsis Diagnosis

The authors say that early diagnosis remains a key challenge in sepsis management. Traditional biomarkers like C-reactive protein and procalcitonin lack specificity and sensitivity. Systems immunology has enabled the development of novel diagnostic gene expression signatures, such as Cellular Reprogramming (CR), which accurately predicts sepsis progression. These signatures can potentially guide early intervention, thereby improving patient outcomes.

“The high mortality rate of sepsis can likely be attributed to 2 factors: difficult and often delayed diagnosis and the lack of sepsis-specific treatments,” the authors wrote. “The difficulty of sepsis diagnosis, especially early in disease, can result in delayed treatment with antibiotics (or monoclonal antibodies and antivirals in the case of COVID-19). This delay has been documented to drastically increase mortality rates: for every hour that appropriate antibiotic therapy is delayed, the in-hospital mortality rate can increase very significantly, with numbers often cited of up to 7.6% in septic shock.”

Longitudinal Analysis: Understanding Sepsis Progression

Sepsis is a dynamic disease, with immune dysfunction evolving. Longitudinal transcriptomic studies have shown that immune dysregulation persists in nonsurvivors while survivors exhibit gradual immune recovery. These findings support:

• Stage-specific therapies: Tailoring treatments based on sepsis progression.
• Predicting mortality risk: Identifying patients at high risk through persistent immune dysfunction markers.
• Understanding post-sepsis syndrome: Addressing long-term immune dysregulation that leads to chronic health issues and frequent hospital readmissions.

Post-Sepsis Syndrome and Long COVID

Survivors of sepsis often experience long-term complications, including immune dysfunction, cognitive impairment, and cardiovascular issues. Long COVID shares similar features with post-sepsis syndrome, suggesting a common underlying mechanism of persistent immune dysregulation. Epigenetic studies indicate that sepsis induces long-lasting changes in immune gene expression, offering potential targets for therapeutic intervention.

Barriers to Implementing Precision Sepsis Care

Despite its promise, the adoption of systems immunology in sepsis care faces several challenges:

• High cost and resource requirements limit widespread implementation.
• Limited availability of large-scale omics datasets hinders robust model validation.
• Lack of suitable animal models makes experimental validation challenging.
• Health care mindset shift is required to transition from traditional sepsis management to precision medicine.

The Path Forward: Multistakeholder Collaboration

A concerted effort from research communities, health care providers, policymakers, and industry stakeholders is needed to realize the potential of precision sepsis care. Key actions include:

• Investment in large-scale multiomics studies to refine sepsis endotypes and biomarkers.
• Development of AI-driven diagnostic tools for real-time clinical application.
• Clinical trials for immune-directed therapies tailored to specific sepsis endotypes.
• Inclusion of sepsis in global pandemic preparedness strategies to reduce mortality in future outbreaks.

Sepsis Caused Most Pandemic Deaths

At the beginning of the COVID-19 pandemic, it became clear that the majority of patients hospitalized with severe cases of COVID-19—particularly those who needed respiratory support or succumbed to the illness—were experiencing viral sepsis. This finding is corroborated by studies examining patients’ clinical records and systems immunology, which reveal common immune mechanisms evolving over time between COVID-19 sepsis and non-COVID-19 sepsis, such as that caused by bacteria.

“Consistent with this,” the authors wrote, “both sepsis types are associated with signatures of cellular reprogramming, organ dysfunction, mortality, and endotypes. Thus, it could be argued that although efforts to identify the SARS-CoV-2 virus were critical to developing prophylactic measures (eg, vaccines), the most severe manifestations of this disease were due to sepsis. Indeed, while the SARS-CoV-2 virus caused nearly 700 million infections, it was the 6.9 million deaths, primarily due to sepsis, that drove the strong public health responses, including isolation measures, and the consequent reduction in commerce.”

Conclusion

Sepsis remains a major global health burden, exacerbated by the COVID-19 pandemic. Systems immunology offers a transformative approach to understanding and managing sepsis by enabling precision diagnostics, patient-specific treatments, and stage-specific interventions. Integrating these innovations into clinical practice and pandemic preparedness strategies will be crucial in reducing sepsis-related mortality and improving long-term outcomes for survivors.